Sanofi (SNY) announced the immediate adoption of influenza strains selected by the Food and Drug Administration to advance the manufacturing ...

Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing and delivery of its vaccine portfolio for the 2025 ...

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

The Human Animal Bond Research Institute (HABRI) and Pet Partners today announced the publication of an important study showing significant reductions in child and parental anxiety and the reduced ...

Attorney General Aaron M. Frey announced a settlement agreement with Sanofi-Aventis U.S. LLC after scrutiny over the ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

There are around 5,000 people with CAD in the US, according to Sanofi. At the moment CAD is managed using off-label therapies, including rituximab and corticosteroid drugs, and sutimlimab's ...

Under the settlement, Mainers who are uninsured or have commercial health insurance will be eligible to purchase monthly ...

Sanofi is tapping San Francisco-based Atomwise for a new AI-fuelled drug discovery deal, paying $20 million for five new drug targets — and possibly spending more than a billion in milestone ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

For the quarter, the S&P 500® Index added 2.41%, while the MSCI EAFE Index slid 8.11%. Click here to read the full commentary ...